Arbutus Biopharma CorporationABUSNASDAQ
LOADING
|||
Net Income Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year net income growth rate
Latest
-406.86%
↓ 420% below average
Average (39q)
-78.22%
Historical baseline
Range
High:117.73%
Low:-1016.08%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -406.86% |
| Q2 2025 | 110.29% |
| Q1 2025 | -95.71% |
| Q4 2024 | 36.44% |
| Q3 2024 | 0.40% |
| Q2 2024 | -10.75% |
| Q1 2024 | 7.44% |
| Q4 2023 | 3.94% |
| Q3 2023 | -17.61% |
| Q2 2023 | -4.62% |
| Q1 2023 | 25.50% |
| Q4 2022 | -24.85% |
| Q3 2022 | -23.78% |
| Q2 2022 | 9.98% |
| Q1 2022 | 26.06% |
| Q4 2021 | -11.29% |
| Q3 2021 | 1.18% |
| Q2 2021 | -18.35% |
| Q1 2021 | 3.88% |
| Q4 2020 | 9.13% |
| Q3 2020 | -33.14% |
| Q2 2020 | -1.63% |
| Q1 2020 | 43.78% |
| Q4 2019 | 70.12% |
| Q3 2019 | -253.86% |
| Q2 2019 | -0.28% |
| Q1 2019 | -27.41% |
| Q4 2018 | 25.43% |
| Q3 2018 | -891.75% |
| Q2 2018 | 117.73% |
| Q1 2018 | 51.49% |
| Q4 2017 | -209.75% |
| Q3 2017 | 36.46% |
| Q2 2017 | 2.00% |
| Q1 2017 | 91.48% |
| Q4 2016 | -1016.08% |
| Q3 2016 | 84.93% |
| Q2 2016 | -718.95% |
| Q1 2016 | -201.56% |
| Q4 2015 | 81.84% |